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Session 1: Introductory lecture and discussion
 Rationale of summary measures of population health
 Main summary measures - theoretical underpinnings
and applications
Session 2: Practical exercise and discussion
 Analyzing burden of disease patterns for selected countries
 Group discussion of differences and meanings
Measuring the burden of disease
How can we objectively compare disease burdens? 
 Prevalence? Number of existing cases in the population 
now
 Incidence? Number of new cases in the population per 
year
 Mortality?
 Morbidity?/Severity?
 Health service attendance? HMIS “Top 10 Diseases”
Measuring the Burden of Disease
Traditionally health evaluated by mortality based
indicators
 Mortality rates - e.g. Under five mortality rates
http://gamapserver.who.int/mapLibrary/Files/Maps/Global_Und
erFiveMortality_2015.png
 Life expectancy:
 Average number of years (life span) at a specific age (or at 
birth)  calculated from life tables
 http://vizhub.healthdata.org/le/
Progress in the last 30 years: Mean age at death
Source: IHME GBD 2010
Life expectancy and economic development
Measuring the Burden of Disease
Mortality based indicators limitations – e.g.
 Not enough to assess population health and
comparative impact of health interventions
 The contribution of chronic diseases, injury, disability
to population health goes unrecorded
Summary measures of population health combine
mortality and morbitity
Why summary measures of burden of disease?
 Can estimate quantitative health benefits from interventions
 Comparison accross conditions, interventions, populations
and points in time
 Assist policy makers in health care planning decisions
 Assist debates on research and development priorities
 Often used in cost-effectiveness analysis as the measure of
the «effect» - informinig resource allocation decisions
Major summary measures of population health
Health expectancy – e.g.
 HALE, Health Adjusted Life Expectancy: Number of years of life 
expectancy lived in perfect health
 Quality Adjusted Life Years (QALYs): Number of years of life of 
any quality added by an intervention 
Health gaps measures
 Disability Adjusted Life Years (DALYs): Future stream of life lost 
due to specific conditions or risks
Steps in calculating summary measures
3 general steps in calculating QALYs or DALYs
1. Describing health: i.e. as a health state or as a disease/condition
2. Developing values or weights for the health state or condition: 
which are called HRQL or disability weights 
3. Combining values for different health states or conditions with 
estimates of life expectancy – time is common metric
Each of these steps includes methodological choices that affect the 
estimates that are obtained
QALYs: origin and rationale
 Developed in the late 1960s primarily for use in cost-effectiveness 
analysis (CEA)
 Sum of time spent in different health states using weights on a scale 
of 0 (dead) to 1 (perfectly healthy) for each health state
 The arithmetic product of duration of life and a measure of quality of 
the remaining life years (health state weight)
 Five years of perfect health = 5 QALYs
 Two years in a state measured as 0.5 of perfect health followed by 
three years of perfect health = 4 QALYs
12
QALYs
 QALYs measure health gains and are calculated – for a certain 
year and condition – as follows:
 QALYs = I * D * QW ≈ P * QW
 I = incidence
 D = duration
 P = prevalence
 QW = quality weight (usually so-called health-related quality of
life (HRQOL) with scale 0=death and 1=full health)
QALYs
Illustration of the life path of changing HRQOL for an individual from 
“now” to that person’s death with and without an intervention
Sarah J. Whitehead, and Shehzad Ali Br Med Bull 
2010;96:5-21
© The Author 2010. Published by Oxford University Press. All rights reserved. For permissions, 
please e-mail: journals.permissions@oxfordjournals.org
QALYs
 HRQL weights not linked to any particular disease, condition, or 
disability
 HRQL weights based on the values of individuals for either their own 
health state (patient weights) or the health states of others that are 
described to them (community weights)
 Descriptive systems including key domains are used to create 
QALYs-
 physical, psychological, and social/role function, health perceptions, and 
symptoms e.g. the EQ-5D (EuroQoL)  - http://www.euroqol.org/
QALYs
 Underlying assumptions of the QALY approach:
 Health is defined as value-weighted time (QALYs) over the relevant 
time horizon.
 Value is measured in terms of preference (desirability).
 Preferences measured across individuals can be aggregated and 
used for the group.
 QALYs can be aggregated across individuals, i.e., a QALY is a 
QALY regardless of who gains/loses it
QALYs
 HRQoL weights, direct or indirect methods (also called generic 
preference-based measures). 
 Direct elicitation methods:
 Visual analogue scale (VAS)
 Time trade-off (TTO)
 Standard gamble (SG). 
Direct measures: Visual analogue scale
Sarah J. Whitehead, and Shehzad Ali Br Med Bull 
2010;96:5-21
© The Author 2010. Published by Oxford University Press. All rights reserved. For permissions, 
please e-mail: journals.permissions@oxfordjournals.org
Direct measures: time trade-off and standard gamble 
(using numerical examples)
Sarah J. Whitehead, and Shehzad Ali Br Med Bull 
2010;96:5-21
© The Author 2010. Published by Oxford University Press. All rights reserved. For permissions, 
please e-mail: journals.permissions@oxfordjournals.org
Indirect elicitation methods
 Indirect elicitation methods involve the use of pre-scored generic 
preference-based measures (also called ‘off-the-shelf’ 
questionnaires or generic multi-attribute systems)
 Health states are described using standardized generic utility 
questionnaires, which cover general aspects of health.
 Generic preference-based measures – e.g.
 EuroQol (EQ)-5D,
 Short Form 6D (SF-6D)
 Health Utilities Index (HUI)
Indirect elicitation methods
QALYs - EQ-5D (EuroQoL)  - http://www.euroqol.org/
DALYs: origin and rationale
 World Bank and WHO Global Burden of Disease 1990 study – 1992-96 
(Murray & Lopez: World Bank 1993, Harvard & WHO 1996)
 To facilitate the inclusion of nonfatal health outcomes in 
debates on international health policy
 To develop objective measure of mortality and disability from a 
condition
 To quantify the burden of disease using a measure that could 
be used for cost-effectiveness analysis
 DALYs measure the gap between a population’s health and a 
hypothetical ideal for health achievement
DALYs
 DALYs attach estimates of HRQL/disability to specific diseases, 
rather than to health states –
 International Classification of Impairments, Disabilities, and Handicaps 
(ICIDH) focusing on disability
 DALYs measure health losses and are calculated – for a certain 
year and condition – as follows:
 DALYs = YLL + YLD 
 YLL = years of life lost (due to premature death)
 YLD = years lived with disability
DALYs
Illustration of the life path of changing DW for an individual from “now” to that 
person’s standard life expectancy with and without an intervention.
Global Burden of Disease – past and future
1998 - 2004 WHO assessments of GBD for 1999-2002 (World Health 
Reports 2000 – 2004, WHO website, reports) 1996)
2005 – 2006 GBD 2001 for Disease Control Priorities Project (Lopez, 
Mathers et al 2006)
2006 – 2010 GBD 2005 Project (IHME Murray)
2008 Global Burden Disease – 2004 update (WHO 2008)
2009 Global Health Risks 2004 (WHO 2009)
2010 Child Causes of Death 2008 (WHO 2010)
2012 GBD 2010  (IHME Murray)
2014-15       GBD 2013 (IHME Murray)
Theoretical basis of YLLs
 How long should people in good health expect to live?  standard 
life expectancy
 Are all people equal?  use of same standard life expectancy 
regardless of local life expectancy
 How to compare years lost due to death with years lived in poor 
health?  disability weights with values between 0 (perfect health) 
and 1 (death)
 Value of healthy year of life equal at all ages?  age weights – now 
removed
 Value of future years of life?  discounting
DALYs - Years of Life Lost 
YLL = N x Lx
YLL =  Years of future life lost due to premature mortality
N =  Number of deaths in the population
Lx =  Standard life expectancy at age of death
X =  Age of death
3 deaths at age 50 = 3 x 34 = 102 YLL
Calculating DALYs:  Age weighting
C * x * e
- * x
C = constant
(0.1658)
x = age
 = 0.04
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Calculating DALYs: Discounting
 Adjusting for societal time preference
 Compares value today with value in the future
 Universal characteristic to prefer a benefit now rather than in the 
future 
 Should we discount future health the same way we discount 
future money?
 Arbitrarily set to 3% in the Standard (old) DALYs
 Little consequence for BOD rankings
 Profound consequence for cost-effectiveness of certain 
interventions and hence choice of interventions in health service 
planning
DALYs - Years of Life with Disability 
YLD = I x DW x d
YLD =   Years of life lived with disability
I =   Number of incident cases in the population
DW =   Disability weight
d =   Duration of disability [years]
4 cases of mild mental retardation due to lead at birth
4 x 0.36 x 80 years = 115 YLD
DALYs - Disability weights 
 Quantify preferences for health states in terms of a single number on an 
interval scale
 0 = full health
 1 = health state equivalent to death
 Disability Weights quantify societal preferences for health states 
 (bigger weight more lost health)
 Disability weights say nothing about the value of the person 
 or their quality of life  or their utility
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Disability weights 2010 – a few examples
Colour code
Cancer Cardiovascular and circulatory diseases Diabetes, digestive, and genitourinary diseases
Hearing and vision loss Infectious disease Injuries
Mental and behavioural disorders Musculoskeletal disorders Neurological disorders
Others
Disability weights in comparison
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Color code:
Cancer
Cardiovascular and 
circulatory diseases
Diabetes, digestive, and 
genitourinary diseases
Hearing and vision loss
Infectious disease
Injuries
Mental and behavioural 
disorders
Musculoskeletal 
disorders
Neurological disorders
Others
Cancer 
(Terminal 
phase)
Quadriplegia
AIDS (no treatment)
AIDS (no treatment)
Mild diarrhoea
Migraine
Migraine
Mild diarrhoea
Gout
Gout
Dental caries
Dental caries
Heart failure
Heart failure
Heroin dependence
Heroin dependence
Quadriplegia
COPD
COPD
Death
Perfect health
Cancer 
(Terminal 
phase)
Hearing loss
Hearing loss
Blindness
Blindness
Comparing disability weights 2010 to 2004
Source: IHME GBD 2010
Data sources for DALYs
Mortality
 Vital registration, sample registration systems, household 
surveys, surveillance systems, epidemiological studies, 
population laboratories (DSSs)
Morbidity / disability
 Disease registers, population based studies, epidemiological 
(longitudinal studies), health facility data (injuries)
Source: WHO, Mathers, Gore and Boerma 2010
Criticisms of DALYs
E.g.
 Patient versus community versus health experts valuations of health
 Age‐based weighting does not favor the young or old.
 Disabilities are additive in nature and could add up to more than 1 
death for persons having more than one disability
 No priority is given to those worse off, unlike the usual societal 
tendencies to help those worse off
 Does not assess qualitative difference in outcomes.
 Discounts future health outcomes
GBD 2010:  What’s new in 2013? 
A new touchstone in public health
486 Authors
All new DALY metrics
1. No age weighting / No discounting
2. New disability weights & methods 
3. 291 diseases   (vs. 166)
4. 67 risk factors  (vs. 10)
5. 23 regions        (vs. 6) 
6. National level estimates for 187 countries
7. 650 million estimates in total
8. Re-estimation back to 1990
9. Trend forecasting
10. Web-based visualization interface
Lancet 380: 9859 pp 2053 – 2260 December 15, 2012 – January 4, 2013
DALYs – Burden of Disease classification 
 Group I: Communicable, maternal, perinatal and 
nutritional conditions
 Group II: Non-communicable diseases
 Group III:  Injuries
GBD patterns by broad cause group
GBD 2010: What’s changed?
Globally: Some highlights …
1. We are living longer, but living longer in poor health
2. 60% drop in under-five mortality since 1990
3. Globally HIV/AIDS is the single largest cause of death in adult women (14.4%) 
4. Road traffic accidents now equal HIV/AIDS (10.7%) as second leading cause of 
death in men
5. New leading risk factors: Physical inactivity and inappropriate diet (low fruit, excess 
salt) accounts for 10% of lost DALYs
6. Chronic disease is replacing premature mortality everywhere except  Africa
7. Tobacco, alcohol, mental health, pain and injury move up in proportion along with 
Alzheimer's, HIV and forces of nature
8. Overweight has replaced under-nutrition as a risk factor for the first time
But global averages hide important information   
What is happening regionally and nationally is more interesting
Lancet 380: 9859 pp 2053 – 2260 December 15, 2012 – January 4, 2013
GBD 2010: What’s changed?
http://vizhub.healthdata.org/gbd-compare/
Health challenges of vulnerable groups in low and
middle income countries
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy 
(HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Aug 27.
Shift in the disease burden towards non communicable
diseases
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life 
expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Aug 27.
GBD Visualizations dash board
Go to demo.. http://viz.healthmetricsandevaluation.org/gbd-compare/
Uses of summary measures of population health
 Comparing the health of one population to the health of 
another population
 Comparing the health of the same population at different 
points in time
 Identifying and quantifying overall health inequalities within 
populations
 Providing appropriate and balanced attention to the effects 
of non-fatal health outcomes on overall population health
Uses of summary measures of population health
 Moving from attributable burden due to diseases and risk 
factors to avertable burden due to interventions
 Informing debates on priorities for health service delivery 
and planning
 Informing debates on priorities for research and 
development in the health sector
 Analyzing the benefits of health interventions for use in cost-
effectiveness analyses
 Estimating the potential gain in population health (DALYs) 
through specified investments in interventions or mixes of 
interventions
Benefits and costs of 47 interventions
Example: Scenarios compared for elimination and 
eradication of Lymphatic Filariasis
Kastner RJ, Tediosi F et al (2015) What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on 
the Impact of Scaling Up Mass Drug Administration Programs. PLoS Negl Trop Dis 9(10)
Key features of the proposed scenarios for elimination and eradication of LF
Impacts of LF elimination and eradication strategies
Cumulative N of DALYs averted 
Stone CM,  Tediosi F et al. Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under 
varying levels of mass drug administration scale-up and geographic coverage. BMJ Global Health 2016;1
Incremental cost-effectiveness plane and 
95% CI ellipses
 Scaling up coverage of MDA faster will accumulate more
benefits and savings
 Health and “economic” support for increasing the intensity of 
MDA programmes
Example: Public health impact and cost-effectiveness of 
RTS,S malaria vaccine
Prediction of the likely pubic health impact and cost-
effectiveness of Malaria vaccine RTS,S for 42 countries
OpenMalaria
code.google.com/p/openmalaria/
GAVI vaccine investment strategy, demand forecasting, delivery 
modality investigations, country specific 
implementation/investigations
Public Health Impact:   EPI
cumulative DALYs averted end 2030 
*most DALYs averted: Burkina 
Faso, Ghana, DRC, Uganda, 
Tanzania, Mozambique, Nigeria
*most DALYs per FV averted:  
Sierra Leone, Cote d’Ivoire, 
Togo, Gabon, Eq. Guinea, 
Cameroon, CAR, The Gambia, 
Guinea-Bissau
Cost-per DALY averted by delivery strategy & EIR
 RTS,S is cost effective, particularly in 
countries with medium levels of 
transmission
 At GDP per capita threshold the
vaccine is cost-effective in more than
half of the countries
 At twice GDP per capita the vaccine is
cost-effective in all countries
considered
 Much variation in CE in low-medium
transmission settings (EIR<10)
 Relatively small differences in CER 
across delivery strategies
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